


# NIRSEVIMAB

Read in conjunction with [Disclaimer](#)

<p align="center"><b>Formulary: Restricted</b></p> <p align="center">For use as per WA Immunisation Schedule and WA Health Communicable Disease Control Directorate guidance.</p>	
<b>Presentation</b>	<p><b>Prefilled Syringe:</b></p> <ul style="list-style-type: none"> <li>• 50 mg in 0.5 mL (purple plunger rod)</li> <li>• 100 mg in 1 mL (light blue plunger rod)</li> </ul>
<b>Drug Class</b>	Monoclonal antibody immunisation
<b>Indication</b>	<p><b>Prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease for:</b></p> <ul style="list-style-type: none"> <li>• All infants entering their first RSV season (born on or after 1st October 2023 – 30th April 2024)</li> <li>• All newborns entering the current RSV season (born on or after 1st May 2024 – 30th Sept. 2024)</li> <li>• For children entering their second RSV season (born on or after 1st Oct 2022 – 30th Sept 2023) with a medical risk condition as defined by <a href="#">WA Health</a>.</li> <li>• Aboriginal or Torres Strait Islander children (born on or after 1st October 2022 – 30th Sept 2024)</li> </ul> <p>Nirsevimab should be administered to all eligible infants in preparation for discharge from hospital.</p> <p><b>NOTE: Parent/Guardian consent is to be obtained prior to administration of all vaccinations.</b></p>
<b>Special Considerations</b>	<ul style="list-style-type: none"> <li>• Avoid use in infants less than 1.6 kg and/or less than 29 weeks corrected gestational age. If considering discharge, consult Infectious Diseases (ID) for further advise in these infants.</li> <li>• For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of nirsevimab is recommended as soon as the child is stable after surgery to ensure adequate nirsevimab serum levels. Refer to the product information for dosing advice.</li> <li>• Contraindicated for infants with severe allergy to any ingredients of nirservimab injection.</li> <li>• Caution should be taken with intramuscular injections for children with thrombocytopenia, coagulation disorders or on anticoagulation therapy.</li> </ul>
<b>Interactions</b>	<ul style="list-style-type: none"> <li>• No interaction studies have been conducted. Interactions with other medications are unlikely.</li> <li>• Nirsevimab can be co-administered with other scheduled vaccines. Ensure a different injection site is used.</li> </ul>
<b>Incompatibility</b>	The contents of the nirsevimab prefilled syringe should not be combined with any fluids or other vaccinations prior to administration.
<b>Side Effects</b>	<b>Uncommon:</b> rash, injection site reaction (pain, redness, swelling), fever.

<b>Monitoring</b>	Clinically observe the infant for 15 minutes post administration for adverse reaction or anaphylaxis. Saturation and cardiorespiratory monitoring is not required following administration.
<b>Storage &amp; Stability</b>	<b>Refrigerate between 2 to 8°C, do not freeze. Protect from light.</b> <ul style="list-style-type: none"> <li>May be kept at room temperature (below 25°C) for up to 8 hours. If not used within 8 hours, the syringe must be discarded. Do not return to the refrigerator.</li> </ul>

<b>INTRAMUSCULAR INJECTION</b>	<b>Presentation</b>	<b>Prefilled Syringe:</b> <ul style="list-style-type: none"> <li>50 mg in 0.5 mL (purple plunger rod)</li> <li>100 mg in 1 mL (light blue plunger rod)</li> </ul>								
	<b>Dosage</b>	<table border="1"> <thead> <tr> <th>Working Weight</th> <th>Dose</th> </tr> </thead> <tbody> <tr> <td>Less than 5 kg</td> <td>50 mg (in 0.5 mL)</td> </tr> <tr> <td>5 kg and greater</td> <td>100 mg (in 1 mL)</td> </tr> </tbody> </table>		Working Weight	Dose	Less than 5 kg	50 mg (in 0.5 mL)	5 kg and greater	100 mg (in 1 mL)	Nirsevimab should be prescribed for all eligible infants in preparation for discharge from hospital. For healthy full term infants, this may mean administering at the same time as their first dose of Hepatitis B vaccination.
		Working Weight		Dose						
		Less than 5 kg		50 mg (in 0.5 mL)						
	5 kg and greater	100 mg (in 1 mL)								
<b>Preparation</b>	<ul style="list-style-type: none"> <li>Visually inspect prefilled syringe for particulate matter and discolouration. Nirsevimab should be a clear to opalescent, colourless to yellow solution.</li> <li>Remove the syringe cap off the nirsevimab syringe and attach a Luer lock needle.</li> </ul>									
<b>Administration</b>	Administer the entire contents of the prefilled syringe as an intramuscular injection as per the <a href="#">Medication Administration Guideline</a> .									

## Related Policies, Procedures, and Guidelines

### HDWA Policies and Information:

[Western Australian Immunisation Schedule](#)

[Respiratory Syncytial Virus](#)

[Respiratory Syncytial Virus \(RSV\) immunisation](#)

[Immunisation education](#)

[2024 RSV Infant Immunisation Program](#)

### Clinical Practice Guidelines:

[Neonatology - Immunisations](#)

### Consumer Information:

[PCH RSV Immunisation for Children Health Facts Sheet](#)

## Pharmaceutical and Medicines Management Guidelines:



### WNHS Cold Chain Management for Medications and Vaccines

#### CAHS Medication Refrigerators and Freezers

## References

AusDI. Beyfortus™ (Nirsevimab) Solution for Injection. In: AusDI By Medical Director [Internet]. Australia: AusDI by Medical Director; 2023 [cited 2024 Mar 20]. Available from: <https://www.ausdi.com/>

## Document history

Keywords	Nirsevimab, Beyfortus, immunisation, RSV, respiratory syncytial virus, monoclonal antibody				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	V1.0				
Date First Issued:	04/04/2024	Last Reviewed:	N/A	Review Date:	01/02/2025
Endorsed by:	Neonatal Directorate Management Group			Date:	05/04/2024
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance		<input checked="" type="checkbox"/>  Std 4: Medication Safety		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.</b>					

**This document can be made available in alternative formats on request for a person with a disability.**

© North Metropolitan Health Service 2024